Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Gains from Investment Securities (2016 - 2026)

Tandem Diabetes Care filings provide 12 years of Gains from Investment Securities readings, the most recent being $29.8 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 10395.5% to $29.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.2 million, a 498.83% increase, with the full-year FY2025 number at $26.2 million, up 498.83% from a year prior.
  • Gains from Investment Securities hit $29.8 million in Q4 2025 for Tandem Diabetes Care, up from -$61000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $29.8 million in Q4 2025 to a low of -$109.8 million in Q4 2022.
  • Median Gains from Investment Securities over the past 5 years was $146000.0 (2024), compared with a mean of -$3.9 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 105650.96% in 2022 and later skyrocketed 10395.5% in 2025.
  • Tandem Diabetes Care's Gains from Investment Securities stood at $104000.0 in 2021, then tumbled by 105650.96% to -$109.8 million in 2022, then skyrocketed by 101.8% to $2.0 million in 2023, then crashed by 114.66% to -$289000.0 in 2024, then skyrocketed by 10395.5% to $29.8 million in 2025.
  • The last three reported values for Gains from Investment Securities were $29.8 million (Q4 2025), -$61000.0 (Q3 2025), and -$2.8 million (Q2 2025) per Business Quant data.